Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells-Reference-Cited by-同舟云学术

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells

Published:2011-06-23 Issue:6 Volume:6 Page:e21428
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Chen Yun-Ju,Huang Wei-Chien,Wei Ya-Ling,Hsu Sheng-Chieh,Yuan Ping,Lin Heather Y.,Wistuba Ignacio I.,Lee J. Jack,Yen Chia-Jui,Su Wu-Chou,Chang Kwang-Yu,Chang Wen-Chang,Chou Tse-Chuan,Chou Chao-Kai,Tsai Chang-Hai,Hung Mien-Chie

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].;M Fukuoka;J Clin Oncol,2003

2. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.;MG Kris;JAMA,2003

3. Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer.;R Perez-Soler;J Clin Oncol,2004

4. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.;TJ Lynch;N Engl J Med,2004

5. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.;JG Paez;Science,2004

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Repurposing and Molecular Insights in the Fight Against Breast Cancer;Biomedical and Pharmacology Journal;2024-06-25

2. Cancer stem cells: a target for overcoming therapeutic resistance and relapse;Cancer Biology & Medicine;2024-02-05

3. Epidermal Growth Factor Receptor Inhibitor Mobocertinib Resensitizes Multidrug-Resistant Cancer Cells by Attenuating the Human ATP-Binding Cassette Subfamily B Member 1 and Subfamily G Member 2;ACS Pharmacology & Translational Science;2023-12-05

4. Flavonoids as receptor tyrosine kinase inhibitors in lung cancer;Journal of Functional Foods;2023-11

5. Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells;International Journal of Molecular Sciences;2023-09-12